WO1986000907A1 - Process for the manufacture of 6alpha-methyl steroids - Google Patents
Process for the manufacture of 6alpha-methyl steroids Download PDFInfo
- Publication number
- WO1986000907A1 WO1986000907A1 PCT/DE1985/000249 DE8500249W WO8600907A1 WO 1986000907 A1 WO1986000907 A1 WO 1986000907A1 DE 8500249 W DE8500249 W DE 8500249W WO 8600907 A1 WO8600907 A1 WO 8600907A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- dione
- hydroxy
- general formula
- group
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims abstract 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
- 150000003431 steroids Chemical class 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000002902 organometallic compounds Chemical class 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- VVCFZCMFPVMFOG-QPAVJXABSA-N (8s,10r,13s,14s)-10,13-dimethyl-6-methylidene-1,2,7,8,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1CC[C@]2(C)C3=CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 VVCFZCMFPVMFOG-QPAVJXABSA-N 0.000 claims 1
- 229930194542 Keto Natural products 0.000 claims 1
- 150000001340 alkali metals Chemical group 0.000 claims 1
- 125000000468 ketone group Chemical group 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 21
- -1 alkyl vinyl ether Chemical compound 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 239000000741 silica gel Substances 0.000 description 15
- 229910002027 silica gel Inorganic materials 0.000 description 15
- 239000012043 crude product Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 5
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 5
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 0 C[C@@](C1)C(C)(CC(CC2)=O)C2(C)[C@@](*)(C(*)C2)C1C(CC1)C2(C)[C@]1(*)O Chemical compound C[C@@](C1)C(C)(CC(CC2)=O)C2(C)[C@@](*)(C(*)C2)C1C(CC1)C2(C)[C@]1(*)O 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- FDSGHYHRLSWSLQ-UHFFFAOYSA-N dichloromethane;propan-2-one Chemical compound ClCCl.CC(C)=O FDSGHYHRLSWSLQ-UHFFFAOYSA-N 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000006053 organic reaction Methods 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- VPWOIQAYKMCWOL-MKZSRGMASA-N (8r,9s,10s,13r)-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@H]12)CC3CC(=O)CC[C@]3(C)[C@H]1CC[C@@]1(C)C2=CC=C1 VPWOIQAYKMCWOL-MKZSRGMASA-N 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N 1-ethenoxybutane Chemical compound CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical compound COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- VMEHOTODTPXCKT-RXMQYKEDSA-N (2R)-2-hydroxy-2-methylbutanenitrile Chemical compound CC[C@@](C)(O)C#N VMEHOTODTPXCKT-RXMQYKEDSA-N 0.000 description 1
- OTSPHSRSIAIVOY-JRMUFCLDSA-N (6s,8s,10r,13s,14s,17r)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,6,7,8,12,14,15,16-octahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1C2=CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 OTSPHSRSIAIVOY-JRMUFCLDSA-N 0.000 description 1
- GUHFLRTWNHWJBS-VLTGGNAYSA-N (8r,9s,10s,13s)-17-acetyl-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1C1=CC=C(C(=O)C)[C@@]1(C)CC2 GUHFLRTWNHWJBS-VLTGGNAYSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- KOPMZTKUZCNGFY-UHFFFAOYSA-N 1,1,1-triethoxybutane Chemical compound CCCC(OCC)(OCC)OCC KOPMZTKUZCNGFY-UHFFFAOYSA-N 0.000 description 1
- UEYOQFVKHFOXBC-PXMKSXJSSA-N 1-[(8r,9s,10r,13s,14s,17r)-17-hydroxy-6,10,13-trimethyl-3-pyrrolidin-1-yl-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C([C@H]1[C@@H]2CC[C@]([C@]2(CC[C@@H]1[C@@]1(C)CC2)C)(O)C(=O)C)C(C)=C1C=C2N1CCCC1 UEYOQFVKHFOXBC-PXMKSXJSSA-N 0.000 description 1
- YXRFQWKNFFQPAQ-LEKSSAKUSA-N 1-[(8s,9s,10r,13s,14s,17s)-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C1C=C2C=CCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 YXRFQWKNFFQPAQ-LEKSSAKUSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- ZDBRPNZOTCHLSP-UHFFFAOYSA-N 1-hydroxycyclohexane-1-carbonitrile Chemical compound N#CC1(O)CCCCC1 ZDBRPNZOTCHLSP-UHFFFAOYSA-N 0.000 description 1
- JZHFFOQSXKDOSX-UHFFFAOYSA-N 1-hydroxycyclopentane-1-carbonitrile Chemical compound N#CC1(O)CCCC1 JZHFFOQSXKDOSX-UHFFFAOYSA-N 0.000 description 1
- WSCUHXPGYUMQEX-KCZNZURUSA-N 11beta-hydroxyandrost-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 WSCUHXPGYUMQEX-KCZNZURUSA-N 0.000 description 1
- FZEAQJIXYCPBLD-UHFFFAOYSA-N 11beta-hydroxyandrostenedione Natural products C1C(=O)CCC2(C)C3C(O)CC(C)(C(CC4)=O)C4C3CCC21 FZEAQJIXYCPBLD-UHFFFAOYSA-N 0.000 description 1
- QWJRZIUNOYNJIQ-UHFFFAOYSA-N 2-ethyl-2-hydroxybutanenitrile Chemical compound CCC(O)(CC)C#N QWJRZIUNOYNJIQ-UHFFFAOYSA-N 0.000 description 1
- MWFMGBPGAXYFAR-UHFFFAOYSA-N 2-hydroxy-2-methylpropanenitrile Chemical compound CC(C)(O)C#N MWFMGBPGAXYFAR-UHFFFAOYSA-N 0.000 description 1
- QHSYUAJRIBLSGK-BPZQZONXSA-N C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2C(C[C@]4([C@H]3CCC4=O)C)OC(=O)C(F)(F)F Chemical compound C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2C(C[C@]4([C@H]3CCC4=O)C)OC(=O)C(F)(F)F QHSYUAJRIBLSGK-BPZQZONXSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- CYTYCFOTNPOANT-UHFFFAOYSA-N Perchloroethylene Chemical group ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QRRVOCXLQYLNEC-PPJDWOAVSA-N [(6s,8s,9s,10r,11s,13s,14s,17r)-17-(2-acetyloxyacetyl)-11-hydroxy-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1([C@@H](C)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O QRRVOCXLQYLNEC-PPJDWOAVSA-N 0.000 description 1
- KKUOMFQETYTATH-FYUCUGLASA-N [2-[(6S,8S,9R,10S,11S,13S,14S,17S)-9-bromo-11-hydroxy-6,10,13-trimethyl-3-oxo-2,6,7,8,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate Chemical compound C(C)(=O)OCC([C@H]1CC[C@H]2[C@@H]3C[C@@H](C4=CC(CC[C@]4(C)[C@]3([C@H](C[C@]12C)O)Br)=O)C)=O KKUOMFQETYTATH-FYUCUGLASA-N 0.000 description 1
- AVFHZOOFYZGDSX-ARVFGIOISA-N [2-[(6s,8s,10r,13s,14s,17r)-17-hydroxy-6,10,13-trimethyl-3-oxo-2,6,7,8,12,14,15,16-octahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1C2=CC[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 AVFHZOOFYZGDSX-ARVFGIOISA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 150000001885 cortisol derivatives Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- KLKFAASOGCDTDT-UHFFFAOYSA-N ethoxymethoxyethane Chemical compound CCOCOCC KLKFAASOGCDTDT-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000005907 ketalization reaction Methods 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- DALKLAYLIPSCQL-YPYQNWSCSA-N methylprednisolone aceponate Chemical compound C1([C@@H](C)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]2(C)C[C@@H]1O DALKLAYLIPSCQL-YPYQNWSCSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- ZAEQTGTVGUJEFV-UHFFFAOYSA-N phenylmethanesulfonate;pyridin-1-ium Chemical compound C1=CC=[NH+]C=C1.[O-]S(=O)(=O)CC1=CC=CC=C1 ZAEQTGTVGUJEFV-UHFFFAOYSA-N 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
Definitions
- the invention relates to the object characterized in the claims.
- the cyanohydrins of the general formula I required for the first reaction step of the process according to the invention preferably carry, as lower alkyl groups R 1 and R 2, those which have 1 to 4 carbon atoms.
- Examples of cyanohydrins which may be mentioned are: 2-hydroxy-2-methyl-butanenitrile, 2-ethyl-2-hydroxy-butanenitrile, 1-hydroxycyclopentane carbonitrile, 1-hydroxy-cyclohexane carbonitrile and in particular 2-hydroxy-2-methyl nitrile propane nitrile.
- the reaction step is carried out in the presence of an excess of cyanohydrin.
- about 2 to 5 moles of cyanohydrin are used to convert one mole of steroid of the general formula I.
- This reaction step is preferably carried out in water-containing lower alcohol (methanol, ethanol, isopropane ⁇ l etc.) as a solvent in the presence of basic catalysts (sodium hydroxide solution, potassium hydroxide solution etc.) at a pH of preferably 7.5 to 11 and a reaction temperature of preferably 10 to 60 ° C carried out, with the reaction mixture metered in as much water that only the desired process from the initially formed isomer mixture product crystallized.
- the optimal reaction conditions are determined using the usual preliminary tests.
- the subsequent reaction of the steroids of the general formula I a with the organometallic compounds of the general formula IV is carried out under conditions which are well known to the person skilled in the art. (See, for example, John Fried and John A. Edwards: Organic Reactions in Steroid Chemistry, van Nostrand Reinhold Company, New York, 1972, Vol. II, page 132 ff).
- the 3-oxo group and the hydroxy groups present are protected in a conventional manner before the reaction is carried out.
- the 3-oxo group can be protected, for example, by ketalization with an alkanediol containing 2 to 6 carbon atoms (glycol, 2,2-dimethyl-1,3-propanediol, etc.) or o-diphenol.
- the reaction is carried out by reacting the reactants in an inert solvent (for example chlorinated hydrocarbons such as dichloromethane, trichloroethane, 1,1,2,2 tetrachlorethylene etc.) in the presence of acids (p-toluenesulfonic acid, sulfuric acid, hydrochloric acid) etc.) and dehydrating agents (for example, trialkyl orthoformate such as trimethoxymethane or trieth ⁇ xymethane).
- an inert solvent for example chlorinated hydrocarbons such as dichloromethane, trichloroethane, 1,1,2,2 tetrachlorethylene etc.
- acids p-toluenesulfonic acid, sulfuric acid, hydrochloric acid
- dehydrating agents for example, trialkyl orthoformate such as trimethoxymethane or trieth ⁇ xymethane.
- the intermediate protection of the hydroxyl groups is expediently carried out by the compounds of the general formula I a with an alkyl vinyl ether with 2 to 8 carbon atoms in the alkyl radical, with 3,4-dihydro-2H-pyran with alkyl bromomethyl ether with 1 to 6 carbon atoms in the alkyl st or with dialkcxymethane with 1 to 6 carbon atoms in implement any alkoxy radical under the conditions of US Pat. No. 4,2 07,316.
- the compound of general formula V thus obtained can be brominated in the 21-position in a manner known per se and the bromine atom can be exchanged for an acyloxy radical having 2 to 6 carbon atoms (preferably the acet ⁇ oxy radical) (see, for example, J. Fried and JA Edwards: Organic Reactions in Steroid Chemistry, vari Nostrand Reinhold Comp., New York, 1972, Vol 2, page 160 ff, 179 ff, 204 ff, 209 ff and 223 ff).
- the compound of the formula V is converted into the corresponding enamine salt in a lower alcohol (methanol, ethanol, propanol or isopropanol) using mineral acids (hydrochloric acid, sulfuric acid, perchloric acid etc.) and the latter is brominated using an alcoholic bromine solution.
- An excess of bromine in the reaction mixture should be avoided as far as possible during this reaction.
- the 21-bromine atom is exchanged directly for the 1-oxoalkyloxy radical by reaction with an alkali metal salt of an alkane carboxylic acid having 2 to 6 carbon atoms (preferably sodium acetate or potassium acetate).
- the compounds of the general formula Ib can also be iodinated directly by means of iodine in the 21-position and this iodine exchanged for the 1-oxoalkyloxy radical.
- the starting compounds for the process according to the invention can be synthesized as follows, for example:
- a mixture of 1.0 g of phosphorus pentoxide and 7.5 g of silica gel is added in portions to 35 ml of anhydrous methylene chloride and 22.5 ml of methylal at room temperature. The mixture is stirred for 3 days at room temperature and a further 11 ml of methylal, 500 mg of phosphorus pentoxide and 3.75 g of silica gel are added. After a further 2 days, the reaction mixture is filtered off with suction, the residue is washed thoroughly with methylene chloride and concentrated to dryness in vacuo. The crude product is purified on 350 g of silica gel using a hexane-ethyl acetate gradient (0-50% ethyl acetate). This gives 3.6 g of 6-methylene-4,9-andr ⁇ stadien-3,17-dione. Melting point 166-167 ° C.
- the crude product is purified on 1.5 kg of silica gel with a hexane-ethyl acetate: 12.0 g of 6 ⁇ -ethyl 1-4.9 (11) -androstadiene-3.17-dione are obtained. Melting point 197-197 ° C. a) 15 ml of trifluoroacetic anhydride are added dropwise at -10 ° C. to 25.0 g of 11 ⁇ -hydroxy-4-androstene-3,17-dione in 120 ml of pyridine. The reaction mixture is precipitated in ice-water, the precipitated product is suction filtered, dissolved in methylene chloride, washed with water and dried over sodium sulfate. The crude product is chromatographed on silica gel using an acetone-hexane gradient. 19.6 g of 11-trifluoroacetoxy-4-androsten-3,17-dione are obtained as a foam.
- Tetrahydrofuran, 12.7 ml of butyl vinyl ether and then 20.0 g of 17ß-cyano-3,3- (2,2-dimethylpropan-1,3-dioxy) -6-methyl5,9 (11) -androstadien-17 ⁇ -ol are added.
- the mixture is 20 min at room temp. stirred and 100 ml of methyl lithium (1 M) was added dropwise.
- the reaction solution is stirred for 2 hours at room temperature, 80 ml of glacial acetic acid and 40 ml of water are added, and the mixture is heated to 110 ° C. for 2 hours. After stirring in a solution of 70.0 g of sodium carbonate in 2 l of water, the crystallization of 17-hydroxy-6 ⁇ -methyl-4,9 (11) -pregnadiene3,20-dione begins.
- the product obtained is stirred in a mixture of 70 ml of acetone, 1 ml of water and 0.3 ml of glacial acetic acid with 30.0 g of potassium acetate under reflux.
- the reaction product is placed in ice water after 2 h.
- the precipitated product is filtered off, dissolved in methylene chloride, washed with water and dried over sodium sulfate.
- 2.3 g of 21-acetoxy-11 ⁇ , 17-dihydroxy6 ⁇ -methyl-4-p rain -3, 20-dione are obtained.
- 4-pregnen-3,20-dione is suspended in 120 ml of methanol and refluxed for 1 h with a mixture of 5 ml of 0.1 M aqueous sodium acetate solution and 4.3 ml of 0.1 N aqueous acetic acid. The mixture is concentrated until cloudy, poured into water and extracted with ethyl acetate. The organic phase is washed with water, dried over sodium sulfate and i. Vac. evaporated to dryness. The crude product is purified on silica gel using a hexane-acetone gradient. Yield 3.8 g of 17-butyryloxy-11 ⁇ , 21dihydroxy-6 ⁇ -methyl-4-pregnen-3,20-dione.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Steroid Compounds (AREA)
Abstract
A process for the manufacture of 6alpha-methyl steroids having general formula (I) in which X is a hydroxy group and Y a hydrogen atom, or X and Y are together a carbon-carbon bond and R1 is a cyano group, an acetyl group or an alkanoyloxy-acetyl group with 2 to 6 carbon atoms in the acyl residue.
Description
Verfahren zur Herstel lung von 6α-Methylsteroiden Process for the preparation of 6α-methyl steroids
Die Erfindung betrifft den in den Patentansprüchen gekennzeichneten Gegenstand.The invention relates to the object characterized in the claims.
Das 11ß,17α,21-Trihydroxy-6α-methyl-1,4-pregnadien-3,20-dion (= Methylprednisolon) ist seit langem bekannt und ist Wirkstoff zahlreicher Arzneimittelspezialitäten. Seit einiger Zeit finden auch Ester dieser Verbindung und solche des analogen Hydrocortison-Derivats zunehmend Beachtung (Europäische Patentanmeldungen 54 786, 72 200, 95 894). Das erfindungsgemäße Verfahren ermöglicht es, diese Verbindungen auf wesentlich einfachere Weise zu synthetisieren, als dies nach den vorbekannten Verfahren möglich ist.The 11ß, 17α, 21-trihydroxy-6α-methyl-1,4-pregnadien-3,20-dione (= methylprednisolone) has been known for a long time and is the active ingredient of numerous pharmaceutical specialties. For some time, esters of this compound and those of the analogous hydrocortisone derivative have also received increasing attention (European patent applications 54 786, 72 200, 95 894). The process according to the invention makes it possible to synthesize these compounds in a much simpler manner than is possible according to the previously known processes.
Die für den ersten Reaktionsschritt des erfindungsgemäßen Verfahrens benötigten Cyanhydrine der allgemeinen Formel I tragen als niedere Alkylgruppen R1 und R2 vorzugsweise solche, die 1 bis 4 Kohlenstoffatome tragen. Als Cyanhydrine seien beispielsveise genannt: Das 2-Hydroxy-2-methyl-butannitril, das 2-Ethyl-2-hydroxy-butannitril, das 1-Hydroxycyclopentancarbonitril, das 1-Hydroxy-cyclohexancarbonitril und insbesondere das 2-Hydroxy-2-methyl-propannitril. Der Reaktionsschritt wird in Gegenwart eines Überschusses an Cyanhydrin durchgeführt. Zweckmäßigerweise verwendet man etwa 2 bis 5 Mol Cyanhydrin zur Umsetzung eines Mols Steroid der allgemeinen Formel I.The cyanohydrins of the general formula I required for the first reaction step of the process according to the invention preferably carry, as lower alkyl groups R 1 and R 2, those which have 1 to 4 carbon atoms. Examples of cyanohydrins which may be mentioned are: 2-hydroxy-2-methyl-butanenitrile, 2-ethyl-2-hydroxy-butanenitrile, 1-hydroxycyclopentane carbonitrile, 1-hydroxy-cyclohexane carbonitrile and in particular 2-hydroxy-2-methyl nitrile propane nitrile. The reaction step is carried out in the presence of an excess of cyanohydrin. Advantageously, about 2 to 5 moles of cyanohydrin are used to convert one mole of steroid of the general formula I.
Dieser Reaktionsschritt wird vorzugsweise in wasserhaltigem niederen Alkohol (Methanol, Ethanol, Isopropanαl etc.) als Lösungsmittel in Gegenwart basischer Katalysatoren (Natronlauge, Kalilauge etc.) bei einem pH-Wert von vorzugsweise 7,5 bis 11 und einer Reaktionstemperatur von vorzugsweise 10 bis 60° C durchgeführt, wobei man der Reaktionsmischung soviel Wasser zudosiert, daß aus dem primär gebildeten Isomerengemisch nur das gewünschte Verfahrens
produkt auskristallisiert. Die optimalen Reaktionsbedingungen werden mittels der üblichen Vorversuche ermittelt.This reaction step is preferably carried out in water-containing lower alcohol (methanol, ethanol, isopropane αl etc.) as a solvent in the presence of basic catalysts (sodium hydroxide solution, potassium hydroxide solution etc.) at a pH of preferably 7.5 to 11 and a reaction temperature of preferably 10 to 60 ° C carried out, with the reaction mixture metered in as much water that only the desired process from the initially formed isomer mixture product crystallized. The optimal reaction conditions are determined using the usual preliminary tests.
Die gewünschtenfalls folgende Umsetzung der Steroide der allgemeinen Formel I a mit den metallorganischen Verbindungen der allgemeinen Formel IV erfolgt unter Bedingungen, wie sie dem Fachmann wohlbekannt sind. (Siehe beispielsweise John Fried and John A. Edwards: Organic Reactions in Steroid Chemistry, van Nostrand Reinhold Company, New York, 1972, Vol. II, Seite 132 ff). Vor Durchführung der Reaktion wird die 3-Oxogruppe und die vorhandenen Hydroxygruppen in üblicher Weise geschützt.If desired, the subsequent reaction of the steroids of the general formula I a with the organometallic compounds of the general formula IV is carried out under conditions which are well known to the person skilled in the art. (See, for example, John Fried and John A. Edwards: Organic Reactions in Steroid Chemistry, van Nostrand Reinhold Company, New York, 1972, Vol. II, page 132 ff). The 3-oxo group and the hydroxy groups present are protected in a conventional manner before the reaction is carried out.
Der Schutz der 3-Oxogruppe kann beispielsweise durch Ketalisierung mit einem 2 bis 6 Kohlenstoffatome enthaltenden Alkandiol (Glykol, 2,2-Dimethyl-1,3-propandiol. etc.) oder o-Diphenol erfolgen. Konventionellerweise führt man die Reaktion in der Weise aus, daß man die Reaktionspartner in einem inerten Lösungsmittel (beispielsweise chlorierte Kohlenwasserstoffe, wie Dichlormethan, Trichlorethan, 1,1,2,2Tetrachlorethylen etc.) in Gegenwart von Säuren (p-Toluolsulfonsäure, Schwefelsäure, Salzsäure etc.) und wasserentziehenden Agentien (beispielsweise Orthoameisensäuretrialkylester wie Trimethoxymethan oder Triethαxymethan) umsetzt.The 3-oxo group can be protected, for example, by ketalization with an alkanediol containing 2 to 6 carbon atoms (glycol, 2,2-dimethyl-1,3-propanediol, etc.) or o-diphenol. Conventionally, the reaction is carried out by reacting the reactants in an inert solvent (for example chlorinated hydrocarbons such as dichloromethane, trichloroethane, 1,1,2,2 tetrachlorethylene etc.) in the presence of acids (p-toluenesulfonic acid, sulfuric acid, hydrochloric acid) etc.) and dehydrating agents (for example, trialkyl orthoformate such as trimethoxymethane or triethαxymethane).
Der intermediäre Schutz der Hydroxygruppen erfolgt zweckmäßigerweise, indem man die Verbindungen der allgemeinen Formel I a mit einem Alky lviny lether mit 2 bis 8 Kohlenstoffatomen im Alkylrest, mit 3,4-Dihydro-2H-pyran mit AlkyIbromethylether mit 1 bis 6 Kohlenstoffatomen im Alky lre st oder mit Dialkcxymethan mit 1 bis 6 Kohlenstoffatomen in
jedem Alkoxyrest unter den Bedingungen der US-Patentschrift 42 07 316 umsetzt.The intermediate protection of the hydroxyl groups is expediently carried out by the compounds of the general formula I a with an alkyl vinyl ether with 2 to 8 carbon atoms in the alkyl radical, with 3,4-dihydro-2H-pyran with alkyl bromomethyl ether with 1 to 6 carbon atoms in the alkyl st or with dialkcxymethane with 1 to 6 carbon atoms in implement any alkoxy radical under the conditions of US Pat. No. 4,2 07,316.
Die sich anschließende Umsetzung mit einer metallorganischenThe subsequent implementation with an organometallic
Verbindung der allgemeinen Formel IV erfolgt ebenfalls unter den Bedingungen, wie sie dem Fachmann wohlbekannt sind (siehe beispielsweise J. Fried and J.A. Edwards: NostrandCompound of the general formula IV also takes place under the conditions which are well known to the person skilled in the art (see, for example, J. Fried and J.A. Edwards: Nostrand
Reinhold Comp., New York, 1972, Vol 2, Seite 132 ff). Nach erfolgter Reaktion werden die Schutzgruppen zweckmäßigerweise mittels saurer Hydrolyse abgespalten.Reinhold Comp., New York, 1972, Vol 2, page 132 ff). After the reaction has taken place, the protective groups are expediently cleaved off by means of acid hydrolysis.
Die sich gegebenenfalls anschließende Umsetzung der Steroide der allgemeinen Formel I b mit Pyrrolidin erfolgt ebenfalls unter Bedingungen, die dem Fachmann wohlbekannt sind (siehe beispielsweise J. Fried and J.A. Edwards: Organic Reactions in Steroid Chemistry, van Nostrand Reinhold Comp. New York, 1972, Vol 1, Seite 377 ff).The subsequent subsequent reaction of the steroids of the general formula Ib with pyrrolidine also takes place under conditions which are well known to the person skilled in the art (see, for example, J. Fried and JA Edwards: Organic Reactions in Steroid Chemistry, van Nostrand Reinhold Comp. New York, 1972, Vol 1, page 377 ff).
Die so erhaltene Verbindung der allgemeinen Formel V kann in an sich bekannter Weise in 21-Position bromiert und das Bromatom gegen einen Acyloxyrest mit 2 bis 6 Kohlenstoffatomen (vorzugsweise den Acetαxyrest) ausgetauscht werden (siehe beispielsweise J. Fried and J.A. Edwards: Organic Reactions in Steroid Chemistry, vari Nostrand Reinhold Comp., New York, 1972, Vol 2, Seite 160 ff, 179 ff, 204 ff, 209 ff und 223 ff). In einer bevorzugten Ausführungsform wird die Verbindung der Formel V in einem niederen Alkohol (Methanol, Ethanol, Propanol oder Isopropanol) mittels Mineralsäuren (Salzsäure, Schwefelsäure, Perchlorsäure etc.) in das entsprechende Enaminsalz überführt, und dieses mittels alkoholischer Brom-Lösung bromiert. Während dieser Umsetzung ist ein Überschuß von Brom im Reaktionsgemisch möglichst zu vermeiden. Nach erfolgter Bromierung kann
das 21-Bromatom direkt durch Umsetzung mit einem Alkalimetallsalz einer Alkancarbonsäure mit 2 bis 6 Kohlenstoffatomen (vorzugsweise Natriumacetat oder Kaliumacetat) gegen den 1-Oxoalkyloxyrest ausgetauscht werden.The compound of general formula V thus obtained can be brominated in the 21-position in a manner known per se and the bromine atom can be exchanged for an acyloxy radical having 2 to 6 carbon atoms (preferably the acetαoxy radical) (see, for example, J. Fried and JA Edwards: Organic Reactions in Steroid Chemistry, vari Nostrand Reinhold Comp., New York, 1972, Vol 2, page 160 ff, 179 ff, 204 ff, 209 ff and 223 ff). In a preferred embodiment, the compound of the formula V is converted into the corresponding enamine salt in a lower alcohol (methanol, ethanol, propanol or isopropanol) using mineral acids (hydrochloric acid, sulfuric acid, perchloric acid etc.) and the latter is brominated using an alcoholic bromine solution. An excess of bromine in the reaction mixture should be avoided as far as possible during this reaction. After bromination can the 21-bromine atom is exchanged directly for the 1-oxoalkyloxy radical by reaction with an alkali metal salt of an alkane carboxylic acid having 2 to 6 carbon atoms (preferably sodium acetate or potassium acetate).
Andererseits kann man die Verbindungen der allgemeinen Formel I b auch direkt mittels Jod in der 21-Position jodieren und dieses Jod gegen den 1-Oxoalkyloxyrest austauschen.On the other hand, the compounds of the general formula Ib can also be iodinated directly by means of iodine in the 21-position and this iodine exchanged for the 1-oxoalkyloxy radical.
Die Ausgangsverbindungen für das erfindungsgemäße Verfahren können beispielsweise wie folgt synthetisiert werden:The starting compounds for the process according to the invention can be synthesized as follows, for example:
la) Eine Lösung von 5,0 g 4,9-Androstadien-3,17-dion inla) A solution of 5.0 g of 4,9-androstadiene-3,17-dione in
35 ml wasserfreiem Methylenchlorid und 22,5 ml Methylal wird bei Raumtemperatur mit einem Gemisch aus 1,0 g Phosphorpentoxid und 7,5 g Kieselgel portionsweise versetzt. Man rührt 3 Tage bei Raumtemperatur und fügt weitere 11 ml Methylal, 500 mg Phosphorpentoxid und 3,75 g Kieselgel hinzu. Nach weiteren 2 Tagen saugt man das Reaktionsgemisch ab, wäscht den Rückstand gründlich mit Methylenchlorid und engt im Vakuum zur Trockne ein. Das Rohprodukt wird an 350 g Kieselgel mit einem Hexan-Essigester Gradienten (0-50 % Essigester) gureinigt. Man erhält so 3,6 g 6-Methylen-4,9-andrαstadien-3,17-dion. Schmelzpunkt 166-167° C.A mixture of 1.0 g of phosphorus pentoxide and 7.5 g of silica gel is added in portions to 35 ml of anhydrous methylene chloride and 22.5 ml of methylal at room temperature. The mixture is stirred for 3 days at room temperature and a further 11 ml of methylal, 500 mg of phosphorus pentoxide and 3.75 g of silica gel are added. After a further 2 days, the reaction mixture is filtered off with suction, the residue is washed thoroughly with methylene chloride and concentrated to dryness in vacuo. The crude product is purified on 350 g of silica gel using a hexane-ethyl acetate gradient (0-50% ethyl acetate). This gives 3.6 g of 6-methylene-4,9-andrαstadien-3,17-dione. Melting point 166-167 ° C.
lb) Eine Suspension von 1,5 g Palladium/Aktivkohle in 80 ml Ethanol und 60 ml Cyclohexen wird 1 Stunde bei 80° C Badtemperatur gerührt und nach Zugabe von 15,0 g 6-Methylen4,9 (11)-androstadien-3,17-dion 12 Stunden unter Rühren erhitzt. Nach dem Abkühlen wird der Katalysator abgesaugt, mit Methylenchlorid gewaschen und die vereinigten Filtrate mit 100 ml konz. Salzsäure 30 Minuten bei Raumtemperatur gerührt. Man engt die Reaktionslösung auf 1/3 ihres Volumens ein, gibt auf Eiswasser und arbeitet wie üblich auf. Das Rohprodukt wird an 1,5 kg Kieselgel mit einem Hexan-Essigester gereinigt: Man erhält 12,0 g 6α-Hethy 1-4,9 (11)-androstadien-3,17-dion. Schmelzpunkt 197-197° C.
a) Zu 25,0 g 11ß-Hydroxy-4-androsten-3,17-dion in 120 ml Pyridin werden bei -10° C tropfenweise 15 ml Trifluoressigsäureanhydrid gegeben. Das Reaktionsgemisch wird in Eis-Wasser ausgefällt, das ausgefallene Produkt abgesaugt, in Methylenchlorid gelöst, mit Wasser gewaschen, und über Natriumsulfat getrocknet. Das Rohprodukt wird an Kieselgel mit einem AcetonHexan-Gradienten chromatographiert. Man erhält 19,6 g 11ßtrifluoracetoxy-4-androsten-3,17-dion als Schaum.lb) A suspension of 1.5 g palladium / activated carbon in 80 ml ethanol and 60 ml cyclohexene is stirred for 1 hour at a bath temperature of 80 ° C. and after addition of 15.0 g 6-methylene4.9 (11) -androstadien-3, 17-dione heated for 12 hours with stirring. After cooling, the catalyst is filtered off, washed with methylene chloride and the combined filtrates with 100 ml of conc. Hydrochloric acid stirred for 30 minutes at room temperature. The reaction solution is concentrated to 1/3 of its volume, poured into ice water and worked up as usual. The crude product is purified on 1.5 kg of silica gel with a hexane-ethyl acetate: 12.0 g of 6α-ethyl 1-4.9 (11) -androstadiene-3.17-dione are obtained. Melting point 197-197 ° C. a) 15 ml of trifluoroacetic anhydride are added dropwise at -10 ° C. to 25.0 g of 11β-hydroxy-4-androstene-3,17-dione in 120 ml of pyridine. The reaction mixture is precipitated in ice-water, the precipitated product is suction filtered, dissolved in methylene chloride, washed with water and dried over sodium sulfate. The crude product is chromatographed on silica gel using an acetone-hexane gradient. 19.6 g of 11-trifluoroacetoxy-4-androsten-3,17-dione are obtained as a foam.
2b) Zu einer Suspension von 5,0 g Natriumacetat in 75 ml Chloroform und 100 ml Formaldehyddiethylacetal gibt man 10 ml Phosphorylchlorid und rührt bei 70° C. Nach 1 Stunde tropft man 5,0 g 11ß-Trifluoracetoxy-4-androsten-3,17-dion in 75 ml Chloroform zu und läßt.18 Stunden bei 70° C rühren. Nach dem Abkühlen versetzt man das Reaktionsgemisch vorsichtig mit Natriumcarbonat bis die wässrige Phase alkalisch ist. Die organische Phase wird mit Wasser neutral gewaschen und über Natriumsulfat getrocknet. Man erhält 3,1 g 6Methylen-11ß-trifluoracetoxy-4-androsten-3,17-dion, die in 60 ml Methanol mit 4,5 ml Triethylamin bei Raumtemperatur gerührt werden. Nach 10 Stunden engt man die Lösung im Vakuum ein und chromatographiert das Rohprodukt an Kieselgel mit einem Aceton-Methylenchlorid-Gradienten. Man erhält 2,4 g 11ß-Hydroxy-6-methylen-4-androsten-3,17-dion.2b) 10 ml of phosphoryl chloride are added to a suspension of 5.0 g of sodium acetate in 75 ml of chloroform and 100 ml of formaldehyde diethylacetal and the mixture is stirred at 70 ° C. After 1 hour, 5.0 g of 11β-trifluoroacetoxy-4-androsten-3 are added dropwise. 17-dione in 75 ml of chloroform and allowed to stir at 70 ° C for 18 hours. After cooling, the reaction mixture is carefully mixed with sodium carbonate until the aqueous phase is alkaline. The organic phase is washed neutral with water and dried over sodium sulfate. 3.1 g of 6methylene-11β-trifluoroacetoxy-4-androsten-3,17-dione are obtained, which are stirred in 60 ml of methanol with 4.5 ml of triethylamine at room temperature. After 10 hours, the solution is concentrated in vacuo and the crude product is chromatographed on silica gel using an acetone-methylene chloride gradient. 2.4 g of 11β-hydroxy-6-methylene-4-androstene-3,17-dione are obtained.
2c) 12,6 g 11 ß-Hydroxy-6-methylen-4-androsten-3,17-dion werden analog Vorschrift 1 b mit Palladium/Aktivkohle in Ethanol und Cyclohexen umgesetzt. Es werden nach Chromatαgraphieren des Rohproduktes an Kieselgel mit einem Hexan-Aceton-Gradienten 9,7 g 11ß-Hydroxy-6α-methyl-4-andrαsten-3,17-dion erhalten. Schmelzpunkt 231-232° C.
Die erhaltenen Verfahrensprodukte und ihre Verwendung als Zwischenprodukte zur Synthese pharmakologisch wirksamer Kortikoide sind bekannt.2c) 12.6 g of 11β-hydroxy-6-methylene-4-androsten-3,17-dione are reacted with palladium / activated carbon in ethanol and cyclohexene analogously to instruction 1b. After chromatographing the crude product on silica gel with a hexane-acetone gradient, 9.7 g of 11β-hydroxy-6α-methyl-4-andrαsten-3,17-dione are obtained. Melting point 231-232 ° C. The process products obtained and their use as intermediates for the synthesis of pharmacologically active corticoids are known.
Die nachfolgenden Ausführungsbeispiele dienen zur Erläuterung des erfindungsgemäßen Verfahrens und der Anwendung der erhaltenen Verfahrensprodukte.
The following exemplary embodiments serve to explain the process according to the invention and the use of the process products obtained.
A. Beispiele betreffend das erfindungsgemäße Verfahren,A. Examples relating to the method according to the invention,
Beispiel 1example 1
a)10.0 g 6α-Methyl-4,9(11)-androstadien-3,17-dion werden in 80 ml Methanol unter Zusatz von 5.0 ml Wasser und 10.0 ml Acetoncyanhydrin suspendiert. Das Gemisch wird unter Rühren auf eine Temperatur von 35-40°C gebracht. Durch Zusatz einer Base (oder Basengemisches) wird der pH-Wert des Reaktionsgemisches auf pH 8.7 bis 9.0 eingestellt. Es erfolgt langsame Auflösung des Steroidketons. Nach etwa 2 h setzt Kristallisation ein. Man gibt nach weiteren 2 h 15 ml Wasser zu, rührt eine weiter Stunde, läßt das Reaktionsgemisch über Nacht stehen, gibt dann 100 ml Wasser zu und kühlt auf +15°C ab. Das Kristallisat wird abgesaugt und nacheinander mit 5proz. Kaliumhydrogenphosphatlösung und Wasser gewaschen und getrocknet.a) 10.0 g of 6α-methyl-4,9 (11) -androstadiene-3,17-dione are suspended in 80 ml of methanol with the addition of 5.0 ml of water and 10.0 ml of acetone cyanohydrin. The mixture is brought to a temperature of 35-40 ° C. with stirring. The pH of the reaction mixture is adjusted to pH 8.7 to 9.0 by adding a base (or base mixture). The steroid ketone is slowly dissolved. After about 2 hours, crystallization begins. After a further 2 h, 15 ml of water are added, the mixture is stirred for a further hour, the reaction mixture is left to stand overnight, then 100 ml of water are added and the mixture is cooled to + 15 ° C. The crystals are suctioned off and successively with 5 percent. Potassium hydrogen phosphate solution and water washed and dried.
Man erhält so das 17ß-Cyano-17α-hydroxy-6α-meϊhyl-4,9(11)androstadien-3-on.The 17β-cyano-17α-hydroxy-6α-methyl-4,9 (11) androstadien-3-one is thus obtained.
b) Eine Lösung von 20.0 g 17ß-Cyano-17α-hydroxy-6α-methyl-4,9(11) androstadien-3-on in 0.5 1 Methylenchlorid wird nach Zusatz von 20.0 g 2,2-Dimethyl-1,3-propandiol, 26.0 ml Orthoameisensäuretriethylester und 250 mg p-Toluolsulfonsäure 1 h bei Raumtemperatur gerührt. Nach dem Verdünnen mit Methylenchlorid wird die Reaktionslösung mit einer NatriumhydrogencarbonatLö s u ng gewa s ch en , übe r Nat r i ums u l fa t get rocknet u nd i.Vak. eingeengt. Das Rohprodukt wird an 350 g Kieselgel mit einem Hexan-Aceton-Gradienten gereinigt. Man isoliert 20.6 g 17ß-Cyano-3,3-(2,2-dimethylpropan-1,3-dioxy)-6-methy 1-5 ,9(11) androstadien-17α-ol.
c) Zu einer 0.2proz. Lösung von p-Toluolsulfonsäure in 30 mlb) A solution of 20.0 g of 17β-cyano-17α-hydroxy-6α-methyl-4,9 (11) androstadien-3-one in 0.5 1 of methylene chloride is added after the addition of 20.0 g of 2,2-dimethyl-1,3- propanediol, 26.0 ml of triethyl orthoformate and 250 mg of p-toluenesulfonic acid were stirred at room temperature for 1 h. After dilution with methylene chloride, the reaction solution is washed with a sodium bicarbonate solution, rocked over sodium sulfate and vacuum. constricted. The crude product is purified on 350 g of silica gel using a hexane-acetone gradient. 20.6 g of 17β-cyano-3,3- (2,2-dimethylpropan-1,3-dioxy) -6-methyl 1-5, 9 (11) androstadien-17α-ol are isolated. c) To a 0.2 percent. Solution of p-toluenesulfonic acid in 30 ml
Tetrahydrofuran werden 12.7 ml Butyl vinylether und anschließend 20.0 g 17ß-Cyano-3,3-(2,2-dimethylpropan-1,3-dioxy)-6-methyl5,9(11)-androstadien-17α-ol hinzugefügt. Das Gemisch wird 20 min bei Raumtemp. gerührt und tropfenweise mit 100 ml Methyllithium (1 M) versetzt. Man rührt die Reaktionslösung 2 h bei Raumtemp., fügt 80 ml Eisessig und 40 ml Wasser hinzu und erhitzt das Gemisch 2 h auf 110°C. Nach dem Einrühren einer Lösung von 70.0 g Natriumcarbonat in 2 1 Wasser beginnt die Kristallisation des 17-Hydroxy-6α-methyl-4,9(11)-pregnadien3,20-dion.Tetrahydrofuran, 12.7 ml of butyl vinyl ether and then 20.0 g of 17ß-cyano-3,3- (2,2-dimethylpropan-1,3-dioxy) -6-methyl5,9 (11) -androstadien-17α-ol are added. The mixture is 20 min at room temp. stirred and 100 ml of methyl lithium (1 M) was added dropwise. The reaction solution is stirred for 2 hours at room temperature, 80 ml of glacial acetic acid and 40 ml of water are added, and the mixture is heated to 110 ° C. for 2 hours. After stirring in a solution of 70.0 g of sodium carbonate in 2 l of water, the crystallization of 17-hydroxy-6α-methyl-4,9 (11) -pregnadiene3,20-dione begins.
d)Eine Suspension von 15.0 g 17α-Hydroxy-6α-methyl-4,9(11)pregnadien-3,20-dion in 120 ml Methanol wird unter Argon auf +56°C Innentemperatur erwärmt und mit 60 ml Pyrrolidin versetzt. Dabei geht die Suspension in Lösung und fällt nach ca. 2 min wieder aus. Man rührt 1 h bei 56°C weiter, überführt das Reaktionsgemisch in ein- Becherglas und rührt 1 h bei 0°C nach. Man saugt den Feststoff ab, wäscht mit wenig kaltem Methanol und viel Hexan nach und trocknet den Rückstand bei 30°C im Vakuumtrockenschrank. Ausbeute 18.5 g 17-Hydroxy-6-methyl-3(N-pyrrolidinyl)-3,5-pregnadien-20-on.d) A suspension of 15.0 g of 17α-hydroxy-6α-methyl-4,9 (11) pregnadiene-3,20-dione in 120 ml of methanol is heated to + 56 ° C. internal temperature under argon and mixed with 60 ml of pyrrolidine. The suspension goes into solution and precipitates again after about 2 minutes. Stirring is continued at 56 ° C. for 1 h, the reaction mixture is transferred to a beaker and stirring is continued at 0 ° C. for 1 h. The solid is filtered off with suction, washed with a little cold methanol and a lot of hexane and the residue is dried at 30 ° C. in a vacuum drying cabinet. Yield 18.5 g of 17-hydroxy-6-methyl-3 (N-pyrrolidinyl) -3,5-pregnadien-20-one.
e)Eine Suspension von 18.5 g 17α-Hydroxy-6-methyl-3-(N-pyrroIidinyI 3,5-pregnadien-20-on in 270 ml Methanol wird bei Raumtemp. mit 4.2 ml Perchlorsäure versetzt, das Reaktionsgemisch auf eine Innentemperatur von 65°C erwärmt und anschließend auf 18-20°C abgekühlt unde) A suspension of 18.5 g of 17α-hydroxy-6-methyl-3- (N-pyrrolidinyI 3,5-pregnadien-20-one in 270 ml of methanol is mixed with 4.2 ml of perchloric acid at room temperature. The reaction mixture is brought to an internal temperature of Heated to 65 ° C and then cooled to 18-20 ° C and
5 min bei 20°C nachgerührt. Man tropft nun eine Lösung von 2.8 ml Brom in 37 ml Methanol derart zu, daß kein gelber Niederschlag ausfällt und die Lösung klar bleibt. Es sollte immer Entfärbung eintreten. Nach weiteren 15 min wird bei 20°C eine Lösung von 8.4 g Kai iumcarbonat in 37 ml Wasser tropfenweise zugesetzt, wobei sich die Lösung verdickt. Man rührt 1 h bei 20°C weiter, wobei der pH-Wert zwischen 9 und 10 liegen sollte. Beim langsamen Zutropfen von 3.3 ml Eisessig tritt
Schaumbildung auf und nach 5 minütigem Rühren beträgt der pH-Wert 7. Nach vorsichtiger Zugabe von 31.6 g Kaliumacetat wird 1.5 h bei 50°C gerührt, das Gemisch bei 50°C konzentriert und auf eine Eiswasser-Kochsalz-Lösung gegeben. Man arbeitet wie üblich auf und isoliert nach Säulenchromatographie 12.6 g 21-Acetoxy-17-hydroxy-6α-methy1-4,9(11)-pregnadien-3,20-dion.Stirred for 5 min at 20 ° C. A solution of 2.8 ml of bromine in 37 ml of methanol is now added dropwise in such a way that no yellow precipitate precipitates and the solution remains clear. Discoloration should always occur. After a further 15 minutes, a solution of 8.4 g potassium carbonate in 37 ml water is added dropwise at 20 ° C., the solution thickening. Stirring is continued for 1 h at 20 ° C., the pH should be between 9 and 10. When slowly adding 3.3 ml of glacial acetic acid Foaming on and after 5 minutes of stirring is pH 7. After careful addition of 31.6 g of potassium acetate, the mixture is stirred at 50 ° C. for 1.5 h, the mixture is concentrated at 50 ° C. and added to an ice-water saline solution. The mixture is worked up as usual and, after column chromatography, 12.6 g of 21-acetoxy-17-hydroxy-6α-methy1-4.9 (11) -pregnadiene-3.20-dione are isolated.
Beispiel 2Example 2
a) 8,0 g 11ß-Hydroxy-6α-methyl-4-androsten-3,17-dion werden analog Beispiel 1 a umgesetzt. Es werden 7,4 g 17ß-Cyano11ß,17α-dihydroxy-6α-methyl-4-androsten-3-on erhalten.a) 8.0 g of 11β-hydroxy-6α-methyl-4-androsten-3,17-dione are reacted analogously to Example 1a. 7.4 g of 17β-cyano11β, 17α-dihydroxy-6α-methyl-4-androsten-3-one are obtained.
b) Aus 7,0 g 17ß-Cyano-11ß,17α-dihydroxy-6α-methyl-4-androsten3-on erhält man analog Beispiel 1 b 7,1 g 17ß-Cyano-3,3(2,2-dimethylpropan-1,3-dioxy)-6-methyl-5-androstenllß, 17o-diol.b) From 7.0 g of 17β-cyano-11ß, 17α-dihydroxy-6α-methyl-4-androsten3-one, 7.1 g of 17ß-cyano-3,3 (2,2-dimethylpropane- 1,3-dioxy) -6-methyl-5-androstenllß, 17o-diol.
c) Aus 6,0 g 17ß-Cyano-3,3-(2,2-dimethylpropan-1,3-dioxy)6-meihyl-5-andrusten-113,17α-diol werden analog. Beispiel 1c 5,8 g 11ß,17-Dihydroxy-6α-methyl-4-pregnen-3,20-dior. erhalten.c) From 6.0 g of 17β-cyano-3,3- (2,2-dimethylpropane-1,3-dioxy) 6-meihyl-5-andrusten-113,17α-diol are analogous. Example 1c 5.8 g of 11β, 17-dihydroxy-6α-methyl-4-pregnen-3.20-dior. receive.
d ) Zu 4.0 g gepulvertem Calclumchlorid in 40 ml Methanol gibt man 4.0 g 11ß, 17-Dihydroxy-6α-methyl-4-pregnen-3,20-dion. Die Suspension wird bei 30°C mit einer Lösung von 4.0 g Calclumchlorid und 6.0 g Iod in 40 ml Methanol tropfenweise versetzt. Nach etwa 2 h (die Lösung ist entfärbt) wird das Reaktionsgemisch bei Raumtemp. mit Methylenchlorid verdünnt, mit Thiosulfatlösung und Wasser gewaschen und über Natriumsulfat getrocknet. Das erhaltene Produkt wird in einem Gemisch aus 70 ml Aceton, 1 ml Wasser und 0.3 ml Eisessig mit 30.0 g Kaliumacetat unter Rückfluß gerührt. Das Reaktionsprodukt wird nach 2 h in Eiswasser gegeben. Das ausgefallene Produkt wird abgesaugt, in Methylenchlorid gelöst, mit Wasser gewaschen und über Natriumsulfat getrocknet. Nach Chromatographieren des Rohproduktes mit einem Hexan-Aceton-Gradienten werden 2.3 g 21 -Acetoxy-11ß, 17-dihydroxy6α-methyl-4-p regnen -3 ,20-dion erhalten.
B. Beispiele betreffend die gewerbliche Verwertbarkeit der Verfahrensprodukted) 4.0 g of 11β, 17-dihydroxy-6α-methyl-4-pregnen-3,20-dione are added to 4.0 g of powdered calcium chloride in 40 ml of methanol. A solution of 4.0 g of calcium chloride and 6.0 g of iodine in 40 ml of methanol is added dropwise to the suspension at 30 ° C. After about 2 h (the solution is decolorized) the reaction mixture is at room temperature. diluted with methylene chloride, washed with thiosulfate solution and water and dried over sodium sulfate. The product obtained is stirred in a mixture of 70 ml of acetone, 1 ml of water and 0.3 ml of glacial acetic acid with 30.0 g of potassium acetate under reflux. The reaction product is placed in ice water after 2 h. The precipitated product is filtered off, dissolved in methylene chloride, washed with water and dried over sodium sulfate. After chromatography of the crude product with a hexane-acetone gradient, 2.3 g of 21-acetoxy-11β, 17-dihydroxy6α-methyl-4-p rain -3, 20-dione are obtained. B. Examples regarding the commercial usability of the process products
Beispiel 1example 1
a) Eine Suspension von 50.0 g 21-Acetoxy-17α-hydroxy-6α-methyl4,9(11)-pregnadien-3,20-dion in 625 ml Diethylenglykoldimethylether wird mit 74.0 g N,N-Dimethylaminopyridin und 74 ml Buttersäureanhydrid 23 h bei 80°C Badtemp. gerührt. Nach dem Verdünnen mit Methylenchlorid wäscht man die Reaktionslösung mit 2 N Salzsäure und unterwirft sie einer Wasserdampfdestillation. Man nimmt das Gemisch in Methylenchlorid auf und arbeitet wie üblich auf. Das Rohprodukt wird an 3.5 kg Kieselgel mit einem Methylenchlorid-Aceton-Gradienten gereinigt. Ausbeute 43.5 g 21-Acetoxy17α-butyryloxy-6α-methyl-4,9(11)-pregnadien-3,20-dion.a) A suspension of 50.0 g of 21-acetoxy-17α-hydroxy-6α-methyl4,9 (11) -pregnadiene-3,20-dione in 625 ml of diethylene glycol dimethyl ether is mixed with 74.0 g of N, N-dimethylaminopyridine and 74 ml of butyric anhydride for 23 hours at 80 ° C bath temp. touched. After dilution with methylene chloride, the reaction solution is washed with 2N hydrochloric acid and subjected to steam distillation. The mixture is taken up in methylene chloride and worked up as usual. The crude product is purified on 3.5 kg of silica gel using a methylene chloride-acetone gradient. Yield 43.5 g of 21-acetoxy17α-butyryloxy-6α-methyl-4,9 (11) -pregnadien-3,20-dione.
Fp.: 200-201°C.Mp .: 200-201 ° C.
b) Eine Lösung von 5.0 g 21-Acetoxy-17α-butyryloxy-6α-methyl4,9(11)-pregnadien-3,20-dion in 80 ml Dioxan und 5 ml Wasser wird nach Zugabe von 3.8 g N-Bromsuccinimid bei 20°C tropfenweise mit einer Lösung von 0.4 ml 70proz. Perchlorsäure in 6 ml Wasser versetzt. Man rührt 1 h bei 20°C Innentemperatur weiter, kühlt auf 15°C herunter und neutralisiert tropfenweise mit einer Lösung aus 16.0 g Natriumacetat und 10.0 g Natriumsulfit inb) A solution of 5.0 g of 21-acetoxy-17α-butyryloxy-6α-methyl4,9 (11) -pregnadien-3,20-dione in 80 ml of dioxane and 5 ml of water is added to 20 after adding 3.8 g of N-bromosuccinimide ° C dropwise with a solution of 0.4 ml 70 percent. Perchloric acid in 6 ml of water. The mixture is stirred for a further 1 h at 20 ° C., cooled to 15 ° C. and neutralized dropwise with a solution of 16.0 g of sodium acetate and 10.0 g of sodium sulfite in
97 ml Wasser. Dabei darf die Innentemperatur 23°C nicht überschreiten. Nach Zugabe von 50 ml Methanol wird das Reaktionsgemisch 15 min bei Raumtemperatur und nach Zugabe von 200 ml Wasser 3 h bei 0°C weitergerührt. Schließlich saugt man den Niederschlag ab, wäscht den Rückstand mit Wasser und trocknet bei 70°C im Vakuumtrockenschrank. Das Rohprodukt wird aus Aceton/Hexan umkristallisiert. Man isoliert 4.2 g 21-Acetoxy9α-brom-17-butyryloxy-11ß-hydroxy-5α-methyl-4-pregnen-3,20-dion.
c) 3.3 g 21-Acetoxy-9α-brom-11ß-hydroxy-6α-methyl-4-pregnen-3,20dion werden in 70 ml wasserfreiem Tetrahydrofuran gelöst und nach Zugabe von 11 ml Tributylzinnhydrid und 30.0 mg Azobisisobutyronitril 2 h refluxiert. Man engt i. Vak. ein und reinigt den Rückstand an 500 g Kieselgel mit einem Hexan-EssigesterGradienten. Ausbeute 1.9 g 21-Acetoxy-17α-butyryloxy-11ß-hydroxy6α-methyl-4-pregnen-3,20-dion.97 ml water. The inside temperature must not exceed 23 ° C. After adding 50 ml of methanol, the reaction mixture is stirred for a further 15 minutes at room temperature and after adding 200 ml of water for 3 hours at 0 ° C. Finally, the precipitate is suctioned off, the residue is washed with water and dried at 70 ° C. in a vacuum drying cabinet. The crude product is recrystallized from acetone / hexane. 4.2 g of 21-acetoxy9α-bromo-17-butyryloxy-11β-hydroxy-5α-methyl-4-pregnen-3,20-dione are isolated. c) 3.3 g of 21-acetoxy-9α-bromo-11β-hydroxy-6α-methyl-4-pregnen-3,20dione are dissolved in 70 ml of anhydrous tetrahydrofuran and refluxed for 2 hours after the addition of 11 ml of tributyltin hydride and 30.0 mg of azobisisobutyronitrile. One constricts i. Vac. and cleans the residue on 500 g of silica gel with a hexane-ethyl acetate gradient. Yield 1.9 g of 21-acetoxy-17α-butyryloxy-11β-hydroxy6α-methyl-4-pregnen-3,20-dione.
Beispiel 2Example 2
a) Eine Lösung von 9.5 g 21-Acetoxy-17-hydroxy-6α-methyl-4,9pregnadϊen-3, 20-dion in 475 ml Dioxan wird mit 9.5 g Dichlordicyanobenzochinon 15 h refluxiert. Nach dem Abkühlen und Abfiltrieren engt man das Filtrat zur Trockne ein. Das Rohprodukt wird an 750 g Kieselgel mit einem Hexan-EssigesterGradienten gereinigt. Rohausbeute 6.1 g 21-Acetoxy-17-hydroxy6α-methyl-1,4,9-pregnatrien-3,20-dion, die in 20 ml siedendem Ethanol tropfenweise mit einer Lösung von 5.73 g Na2S2O5 in 8 ml Wasser behandelt werden. Nach 2 h wird das Reaktionsgemisch in der Weise destilliert, daß das Volumen in der Destillationsblase durch Wasserzufuhr erhalten bleibt und das Brückenthermometer 99°C anzeigt. Man kühlt die Destillationsblase auf -20°C ab, filtriert ab, wäscht den Rückstand gründlich mit Wasser und löst ihn in Methylenchlorid. Die organische Lösung wird nach dem Trocknen über eine Kieselgelschicht filtriert und anschließend eingeengt. Ausbeute 4.7 g.
b) Eine Suspension von 11.0 g 21-Acetoxy-17.-hydroxy-6α-methyl1,4,9-pregnatrien-3,20-dion in 140 ml Propionsäure wird auf 0°C abgekühlt und nach dem Zutropfen von 50 ml Trif luoressigsäureanhydrid 2 h bei Raumtemp. gerührt. Nach der Eiswasser-KochsalzFällung filtriert man ab und arbeitet wie üblich auf. Das Rohprodukt wird an Kieselgel mit einem Hexan-Essigester-Gradienten gereinigt. Ausbeute 9.8 g 21-Acetσxy-6α-methyl-17-propionyloxy1,4,9-pregnatrien-3,20-dion.a) A solution of 9.5 g of 21-acetoxy-17-hydroxy-6α-methyl-4,9pregnadϊen-3, 20-dione in 475 ml of dioxane is refluxed with 9.5 g of dichlorodicyanobenzoquinone for 15 h. After cooling and filtering, the filtrate is concentrated to dryness. The crude product is purified on 750 g of silica gel using a hexane-ethyl acetate gradient. Crude yield 6.1 g of 21-acetoxy-17-hydroxy6α-methyl-1,4,9-pregnatrien-3,20-dione, added dropwise in 20 ml of boiling ethanol with a solution of 5.73 g of Na 2 S 2 O 5 in 8 ml of water be treated. After 2 hours, the reaction mixture is distilled in such a way that the volume in the still is maintained by adding water and the bridge thermometer shows 99 ° C. The distillation column is cooled to -20 ° C., filtered, the residue is washed thoroughly with water and dissolved in methylene chloride. After drying, the organic solution is filtered through a layer of silica gel and then concentrated. Yield 4.7 g. b) A suspension of 11.0 g of 21-acetoxy-17.-hydroxy-6α-methyl1,4,9-pregnatrien-3,20-dione in 140 ml of propionic acid is cooled to 0 ° C. and after the dropwise addition of 50 ml of trifluoroacetic anhydride 2 h at room temp. touched. After the ice water / salt salt precipitation, filter off and work up as usual. The crude product is purified on silica gel using a hexane-ethyl acetate gradient. Yield 9.8 g of 21-acetσxy-6α-methyl-17-propionyloxy1,4,9-pregnatrien-3,20-dione.
c) 5.0 g 21-Acetoxy-6α-methyl-17-propionyloxy-1,4,9-pregnatrien3,20-dion werden in 60 ml Dioxan gelöst und nach Zugabe yon 5.0 g N-Bromsuccinimid tropfenweise mit 150 ml einer 10proz. Perchlorsäure versetzt. Man rührt 0.5 h bei Raumtemp., gibt auf Eiswasser und arbeitet wie üblich auf. Man isoliert 5.5 g 2,-Acetααy-9α-brom-11ß-hydroxy-5α-methyl-17-propionyloxy-1,4pregnadien-3,20-dion.c) 5.0 g of 21-acetoxy-6α-methyl-17-propionyloxy-1,4,9-pregnatrien3,20-dione are dissolved in 60 ml of dioxane and, after adding 5.0 g of N-bromosuccinimide, dropwise with 150 ml of a 10 percent. Perchloric acid added. The mixture is stirred at room temperature for 0.5 h, poured into ice water and worked up as usual. 5.5 g of 2, -acetααy-9α-bromo-11β-hydroxy-5α-methyl-17-propionyloxy-1,4pregnadiene-3,20-dione are isolated.
d)d)
Analog Beispiel 8 werden 5.0 g 21-Acetoxy-9α-brom-11ß-hydroxy6α-methyl-17α-propionyloxy-1,4-pregnadien-3,20-dion mit Tributylzinnhydrid debromiert, aufgearbeitet und gereinigt. Man isoliertAnalogously to Example 8, 5.0 g of 21-acetoxy-9α-bromo-11β-hydroxy6α-methyl-17α-propionyloxy-1,4-pregnadiene-3,20-dione are debrominated with tributyltin hydride, worked up and purified. One isolates
2.3 g 21-Acetoxy-11ß-hydroxy-6α-methyl-17-propionyloxy-1,4pregnadien-3,20-dion.
B eis pi el 32.3 g of 21-acetoxy-11β-hydroxy-6α-methyl-17-propionyloxy-1,4pregnadiene-3,20-dione. Ice pi el 3
a) Eine Lösung von 7.0 g 21-Acetoxy-11ß,17-dihydroxy-6α-methyl-4pregnen-3,20-dion in 80 ml methanolischer 0.2 N Kaliumhydroxidlösung wird 40 min bei 0°C gerührt. Man neutralisiert mit 10proz. Essigsäure und erhält nach der Eiswasserfällung und Aufarbeitung ein Rohprodukt, das an Kieselgel mit einem Methylenchlorid-Aceton-Gradienten gereinigt wird. Ausbeute 4.9 g 11ß,17,21-Trihydroxy-6α-methyl-4-pregnen-3,20-dion.a) A solution of 7.0 g of 21-acetoxy-11ß, 17-dihydroxy-6α-methyl-4pregnen-3,20-dione in 80 ml of methanolic 0.2 N potassium hydroxide solution is stirred at 0 ° C for 40 min. You neutralize with 10 percent. Acetic acid and after the ice water precipitation and work-up a crude product that is purified on silica gel with a methylene chloride-acetone gradient. Yield 4.9 g of 11β, 17,21-trihydroxy-6α-methyl-4-pregnen-3,20-dione.
b) 4.2 g 11ß,17,21-Trihydroxy-6α-methyl-4-pregnen-3,20-dion und 420 mg Pyridiniumtoluolsulfonat werden in 200 ml Methyl-tbutylether (Driveron S) unter Argon suspendiert. Bei einerb) 4.2 g of 11β, 17,21-trihydroxy-6α-methyl-4-pregnen-3,20-dione and 420 mg of pyridinium toluenesulfonate are suspended in 200 ml of methyl t-butyl ether (Driveron S) under argon. At a
Innentemperatur von 58°C werden 50 ml Driveron S abdestilliert, der Ansatz auf 40°C abgekühlt, mit 10 ml Orthobuttersäuretriethylester versetzt und anschließend 2 h am Rückfluß gekocht, so daß keine ungelösten Bestandteile mehr vorhanden sind. Man fügt 5 ml Pyridin hinzu und engt die Lösung ein. Man erhältInternal temperature of 58 ° C., 50 ml of Driveron S are distilled off, the mixture is cooled to 40 ° C., 10 ml of orthobutyric acid triethyl ester are added and the mixture is then refluxed for 2 hours, so that no undissolved constituents are present. 5 ml of pyridine are added and the solution is concentrated. You get
17,21-(1-Ethoxybutylidendioxy)-11ß-hydroxy-6α-methyl-4-pregnen¬17,21- (1-ethoxybutylidenedioxy) -11β-hydroxy-6α-methyl-4-pregnen¬
3,20-dion als Öl.3.20-dione as an oil.
Das rohe 17,21-(1-Ethoxybutylidendioxy)-11ß-hydroxy-6α-methyl¬The crude 17,21- (1-ethoxybutylidendioxy) -11ß-hydroxy-6α-methyl¬
4-pregnen-3,20-dion wird in 120 ml Methanol suspendiert und mit einem Gemisch aus 5 ml 0.1 M wäßriger Natriumacetat-Lösung und 4.3 ml 0.1 N wäßriger Essigsäure 1 h refluxiert. Man engt bis zur Trübung ein, gibt auf Wasser und extrahiert mit Essigester. Die organische Phase wird mit Wasser gewaschen, über Natriumsulfat getrocknet und i. Vak. zur Trockne eingedampft. Das Rohprodukt wird an Kieselgel mit einem Hexan-AcetonGradienten gereinigt. Ausbeute 3.8 g 17-Butyryloxy-11ß,21dihydroxy-6α-methyl-4-pregnen-3,20-dion.
Eine Lösung von 3.2 g 17 -Butyryloxy-11ß,21-dihydroxy-6α-methyl4-pregnen-3,20-dion in 32 ml Pyridin und 16 ml Essigsäureanhydrid wird 1 h bei Raumtemp. gerührt. Nach Eiswasserfällung und üblicher Aufarbeitung isoliert man 3.4 g 21-Acetoxy-17-butyryloxy-11ßhydroxy-6α-methyl-4-pregnen-3,20-dion.
4-pregnen-3,20-dione is suspended in 120 ml of methanol and refluxed for 1 h with a mixture of 5 ml of 0.1 M aqueous sodium acetate solution and 4.3 ml of 0.1 N aqueous acetic acid. The mixture is concentrated until cloudy, poured into water and extracted with ethyl acetate. The organic phase is washed with water, dried over sodium sulfate and i. Vac. evaporated to dryness. The crude product is purified on silica gel using a hexane-acetone gradient. Yield 3.8 g of 17-butyryloxy-11β, 21dihydroxy-6α-methyl-4-pregnen-3,20-dione. A solution of 3.2 g of 17-butyryloxy-11β, 21-dihydroxy-6α-methyl4-pregnen-3,20-dione in 32 ml of pyridine and 16 ml of acetic anhydride is at room temperature for 1 h. touched. After ice water precipitation and customary work-up, 3.4 g of 21-acetoxy-17-butyryloxy-11βhydroxy-6α-methyl-4-pregnen-3,20-dione are isolated.
Claims
1. Verfahren zur Herstellung von 6α-Methylsteroiden der allgemeinen Formel I1. Process for the preparation of 6α-methyl steroids of the general formula I
worinwherein
X eine Hydroxygruppe und Y ein Wasserstoffatom, oderX is a hydroxy group and Y is a hydrogen atom, or
X und Y gemeinsam eine Kohlenstoff-Kohlenstcffbindung bedeuten undX and Y together represent a carbon-carbon bond and
R1 eine Cyangruppe, eine Acetylgruppe oder eine Alkanoyloxy-acetylgruppe mit 2 bis 6 Kohlenstoffatomen imR 1 is a cyano group, an acetyl group or an alkanoyloxyacetyl group having 2 to 6 carbon atoms in the
Acylrest bedeutet, dadurch gekennzeichnet, daß man einAcyl radical, characterized in that one
Steroid der allgemeinen Formel IISteroid of the general formula II
CH.CH.
worinwherein
X und Y die obengenannte Bedeutung besitzen in Gegenwart von Basen mit einem Cyanhydrin der allgemeinen Formel III X and Y have the meaning given above in the presence of bases with a cyanohydrin of the general formula III
worinwherein
R2 und R3 niedere Alkylgruppen oder gemeinsam eine Tetramethylengruppe oder eine Pentamethylengruppe darstellen umsetzt, gewünschtenfalls das erhaltene Steroid der allgemeinen Formel I aR 2 and R 3 are lower alkyl groups or together represent a tetramethylene group or a pentamethylene group, if desired the steroid obtained of the general formula I a
worinwherein
X und Y die obengenannte Bedeutung besitzen nach intermediärem Schutz der Keto- und Hy droxygruppe mit einer metallorganischen Verbindung der allgemeinen Formel IVX and Y have the abovementioned meaning after intermediate protection of the keto and hydroxy group with an organometallic compound of the general formula IV
Me-CH3 (IV)Me-CH 3 (IV)
worinwherein
Me ein Alkalimetallatom oder einen Magnesiumhalogenidrest bedeutet, umsetzt, gewünschtenfalls das erhaltene Steroid der allgemeinen Formel Ib Me represents an alkali metal atom or a magnesium halide residue, reacted, if desired, the steroid obtained of the general formula Ib
worinwherein
X und Y die obengenannte Bedeutung besitzen, mit Pyrrolidin zur Verbindung der allgemeinen Formel VX and Y have the meaning given above, with pyrrolidine to the compound of the general formula V.
worinwherein
X und Y die obengenannte Bedeutung besitzen umsetzt, und gewünschtenfalls dieses in der 21-Position bromiert, das Brom gegen einen 1-Oxoalky lrest mit 2 bis 6 Kohlenstoffatomen austauscht und die Schutzgruppe hydrolytisch abspaltet. X and Y have the meaning given above, and if desired brominated in the 21-position, the bromine is replaced by a 1-oxoalkyl radical having 2 to 6 carbon atoms and the protective group is split off hydrolytically.
2. 6α-Methyl-4,9(11)-androstadien-3,17-dion.2. 6α-methyl-4,9 (11) -androstadiene-3,17-dione.
3. 17ß-Cyanα-17α-hydroxy-6α-methyl-4,9(11)-androstadien3-on.3. 17ß-Cyanα-17α-hydroxy-6α-methyl-4,9 (11) -androstadien3-one.
4. 11ß-Hydroxy-6α-methyl-4-androsten-3,17-dion.4. 11β-hydroxy-6α-methyl-4-androsten-3,17-dione.
5. 17ß-Cyano-11ß,17α-dihydroxy-6α-methyl-4-androsten-3-on,5. 17β-cyano-11ß, 17α-dihydroxy-6α-methyl-4-androsten-3-one,
6. 6-Methylen-4,9(11)-androstadien-3,17-dion.6. 6-methylene-4,9 (11) -androstadiene-3,17-dione.
7. 11ß-Hydroxy-6-methylen-4-androstsn-3,17-dion. 7. 11β-Hydroxy-6-methylene-4-androstsn-3,17-dione.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19843427486 DE3427486A1 (en) | 1984-07-23 | 1984-07-23 | METHOD FOR PRODUCING 6 (ALPHA) METHYLSTEROIDS |
DEP3427486.3 | 1984-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1986000907A1 true WO1986000907A1 (en) | 1986-02-13 |
Family
ID=6241571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1985/000249 WO1986000907A1 (en) | 1984-07-23 | 1985-07-22 | Process for the manufacture of 6alpha-methyl steroids |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0187847A1 (en) |
JP (1) | JPS61502960A (en) |
DE (1) | DE3427486A1 (en) |
PL (1) | PL254621A1 (en) |
WO (1) | WO1986000907A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988003534A1 (en) * | 1986-11-05 | 1988-05-19 | The Upjohn Company | STEROIDAL 17alpha-SILYL ETHERS AND PROCESS TO CORTICOIDS AND PROGGESTERONES |
WO1995030684A1 (en) * | 1994-05-09 | 1995-11-16 | Pharmacia & Upjohn Company | SYNTHESIS OF 17β-CYANO-3-ETHOXY-17α-HYDROXY-6-METHYLANDROSTA-3,5,9(11)-TRIENE |
US5972922A (en) * | 1990-06-11 | 1999-10-26 | Alcon Laboratories, Inc. | Steroids which inhibit angiogenesis |
WO2011130877A1 (en) * | 2010-04-21 | 2011-10-27 | 天津金耀集团有限公司 | Crystalline form of methylprednisolone aceponate monohydrate and preparation methods thereof |
CN103601786A (en) * | 2013-11-22 | 2014-02-26 | 湖南新合新生物医药有限公司 | Preparation method of methylprednisolone key intermediate |
CN105017364A (en) * | 2015-07-06 | 2015-11-04 | 湖南新合新生物医药有限公司 | Methylprednisolone intermediate, preparation method therefor and application thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3931064A1 (en) * | 1989-09-14 | 1991-03-28 | Schering Ag | METHOD FOR PRODUCING PROGESTERONE DERIVATIVES |
CN111748010B (en) * | 2019-03-29 | 2023-12-08 | 天津药业研究院股份有限公司 | Methylprednisolone aceponate anhydrous crystal type and composition thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0054786A1 (en) * | 1980-12-23 | 1982-06-30 | Schering Aktiengesellschaft | 6-Alpha-methyl hydrocortisone derivatives, their preparation and their utilization |
EP0153001A2 (en) * | 1984-02-03 | 1985-08-28 | The Upjohn Company | Steroids having an enamide or enimide group and their preparation |
JPH08262296A (en) * | 1995-03-23 | 1996-10-11 | Mitsubishi Cable Ind Ltd | Optical fiber cable |
-
1984
- 1984-07-23 DE DE19843427486 patent/DE3427486A1/en not_active Withdrawn
-
1985
- 1985-07-19 PL PL25462185A patent/PL254621A1/en unknown
- 1985-07-22 EP EP19850903811 patent/EP0187847A1/en not_active Withdrawn
- 1985-07-22 JP JP50353885A patent/JPS61502960A/en active Pending
- 1985-07-22 WO PCT/DE1985/000249 patent/WO1986000907A1/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0054786A1 (en) * | 1980-12-23 | 1982-06-30 | Schering Aktiengesellschaft | 6-Alpha-methyl hydrocortisone derivatives, their preparation and their utilization |
EP0153001A2 (en) * | 1984-02-03 | 1985-08-28 | The Upjohn Company | Steroids having an enamide or enimide group and their preparation |
JPH08262296A (en) * | 1995-03-23 | 1996-10-11 | Mitsubishi Cable Ind Ltd | Optical fiber cable |
Non-Patent Citations (2)
Title |
---|
CHEMICAL ABSTRACTS, Vol. 97, No. 17, 25 October 1982, Columbus, Ohio (US) see page 719, Abstract 145148s, & JP, A, 8262296 (Mitsubishi) 15 April 1982 * |
JOHN FRIED, JOHN A. EDWARDS, Organic Reactions in Steroid Chemistry, Vol. II, published in 1972 Van Nostrand Reinhold Company, New York (US), see page 223 (cited in the application) * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988003534A1 (en) * | 1986-11-05 | 1988-05-19 | The Upjohn Company | STEROIDAL 17alpha-SILYL ETHERS AND PROCESS TO CORTICOIDS AND PROGGESTERONES |
EP0268400A1 (en) * | 1986-11-05 | 1988-05-25 | The Upjohn Company | Steroidal 17alpha-silyl ethers and process to corticoids and progesterones |
US5972922A (en) * | 1990-06-11 | 1999-10-26 | Alcon Laboratories, Inc. | Steroids which inhibit angiogenesis |
WO1995030684A1 (en) * | 1994-05-09 | 1995-11-16 | Pharmacia & Upjohn Company | SYNTHESIS OF 17β-CYANO-3-ETHOXY-17α-HYDROXY-6-METHYLANDROSTA-3,5,9(11)-TRIENE |
AU684946B2 (en) * | 1994-05-09 | 1998-01-08 | Pharmacia & Upjohn Company | SYNTHESIS OF 17B CYANO-3-ETHOXY-17a-HYDROXY-6-METHYLANDROSTA-3,5,9-(11)-TRIEN 9(11)-triene |
WO2011130877A1 (en) * | 2010-04-21 | 2011-10-27 | 天津金耀集团有限公司 | Crystalline form of methylprednisolone aceponate monohydrate and preparation methods thereof |
CN103601786A (en) * | 2013-11-22 | 2014-02-26 | 湖南新合新生物医药有限公司 | Preparation method of methylprednisolone key intermediate |
CN105017364A (en) * | 2015-07-06 | 2015-11-04 | 湖南新合新生物医药有限公司 | Methylprednisolone intermediate, preparation method therefor and application thereof |
Also Published As
Publication number | Publication date |
---|---|
DE3427486A1 (en) | 1986-01-30 |
EP0187847A1 (en) | 1986-07-23 |
PL254621A1 (en) | 1986-06-17 |
JPS61502960A (en) | 1986-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0100874B1 (en) | 6,16-dimethyl corticoids, their preparation and their use | |
DE68911157T2 (en) | Synthesis of 6-methylene androsta-1,4-diene-3,17-dione derivatives. | |
WO1986000907A1 (en) | Process for the manufacture of 6alpha-methyl steroids | |
DE60021422T2 (en) | A process for the preparation of 17α-acetoxy-11β- [4-n, n- (dimethylamino) phenyl] -21-methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates and processes useful in the process for the preparation of such intermediates | |
US4325879A (en) | Amino-14 steroid derivatives and process for preparation of the same | |
EP0181442B1 (en) | Process for the preparation of pregnane derivative | |
DE2604055A1 (en) | 9 ALPHA-FLUOR-DELTA HIGH 4 -PREGNEN- AND -DELTA HIGH 1.4 -PREGNADIEN SQUARE BRACKETS ON 16 ALPHA, 17-SQUARE BRACKETS FOR CYCLOHEXEN-3.20-DIONE CONNECTIONS | |
GB2152058A (en) | 17-ethynyl-6-fluoro steroids, their preparation and use | |
DE2748442C3 (en) | 17? - (3-iodobenzoyloxy) -9? -chlor4-pregnen-3.20-dione, intermediates and process for their preparation, 9? -chlor-17α, 21-dihydroxy-1,4-pregnadiene-3,20-dione and drugs containing it | |
EP0201452B1 (en) | Process for the preparation of 17-alpha-ethynyl-17-beta-hydroxy-18-methyl-estra-4,15-dien-3-one and the starting products for this process | |
EP0591268A1 (en) | Method for the preparation of 6-methylene steroids | |
US4472310A (en) | 5β-Hydroxy-Δ6 -steroids and process for the preparation thereof | |
DE2803660A1 (en) | NEW IN 17-POSITION SUBSTITUTED STEROIDS OF THE PREGN SERIES, THEIR PRODUCTION AND USE | |
CH624684A5 (en) | ||
US4416821A (en) | Process for preparing 16-methylene steroids | |
DE3715869C2 (en) | ||
EP0378563B1 (en) | Conversion of steroidal 17-cyanohydrins to corticoids | |
EP1339734B1 (en) | Method for the production of 4-(17alpha substituted 3-oxoestra-4,9-dien-11beta-yl)benzaldehyd-(1e or 1z)-oximes | |
DE2521231A1 (en) | METHOD FOR PRODUCING 21-HYDROXY-16-PREGNEN-20-ONE DERIVATIVES | |
EP1056769B1 (en) | 15-methyl-cyclopropanosteroids and method for the production thereof | |
DE2749104C2 (en) | Process for the preparation of?? 15? -Steroids | |
EP0164298A2 (en) | 6-Alpha-methyl-D-homo-corticoids | |
DE1593348C3 (en) | Process for the preparation of 19-fluoro-steroid epoxies and 19-fluoro-11,19-epoxy steroids | |
DE2754759A1 (en) | 3ALPHA-HYDROXY-5BETA-CHOLEST-24-EN-COMPOUNDS AND METHOD FOR THEIR PRODUCTION | |
DE1593687C (en) | Process for the production of new benzo square bracket on d, square bracket mer to steroids of the androstane and preg nan series |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Designated state(s): BG HU JP SU US |
|
AL | Designated countries for regional patents |
Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1985903811 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1985903811 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1985903811 Country of ref document: EP |